-
12:10:22 PM

MRTX Stock News

05/24/23 4:01 PM
Nasdaq : MRTX
clinical trial
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Mirati Therapeutics, Inc. ®, a commercial-stage oncology company, today announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis. SAPPHIRE is a Phase 3 study evaluating sitravatinib in combination with nivolumab 1 versus docetaxel in patients with second or third line...
RHEA-AI
positive
04/27/23 4:30 PM
Nasdaq : MRTX
conferences
Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference
Mirati Therapeutics, Inc. ®, a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T./ 1:00 p.m. E.T. Ben Hickey, chief commercial officer, will represent the company in a fireside chat at the conference. About Mirati Therapeutics, Inc. ®. Mirati Therapeutics, Inc. is a...
RHEA-AI
neutral
04/26/23 4:34 PM
Nasdaq : MRTX
clinical trial
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
Mirati Therapeutics, Inc. ®, a commercial stage biotechnology company, announced today the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective KRAS G12C inhibitor, is well tolerated and demonstrates meaningful clinical activity in patients with pancreatic ductal adenocarcinoma, biliary...
RHEA-AI
neutral
04/25/23 4:30 PM
Nasdaq : MRTX
conferencesearnings
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
Mirati Therapeutics, Inc., a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023. During a conference call at 4:30 p.m. ET/ 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results. Mirati Therapeutics, Inc.is a...
RHEA-AI
neutral
04/03/23 4:00 PM
Nasdaq : MRTX
conferences
Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs
Mirati Therapeutics, Inc., a commercial stage biotechnology company, today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRAS G12C inhibitor, or an...
RHEA-AI
neutral